BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33535808)

  • 1. Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells.
    Qian J; Yang M; Feng Q; Pan XY; Yang LL; Yang JL
    Exp Biol Med (Maywood); 2021 May; 246(10):1228-1238. PubMed ID: 33535808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
    Lin XR; Zhou XL; Feng Q; Pan XY; Song SL; Fang H; Lei J; Yang JL
    J Cancer Res Clin Oncol; 2019 May; 145(5):1123-1132. PubMed ID: 30796510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.
    Liu FR; Bai S; Feng Q; Pan XY; Song SL; Fang H; Cui J; Yang JL
    BMC Cancer; 2018 Nov; 18(1):1087. PubMed ID: 30419845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer.
    Dai F; Zhang PB; Feng Q; Pan XY; Song SL; Cui J; Yang JL
    J Cancer; 2021; 12(9):2768-2776. PubMed ID: 33854636
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression.
    Wang M; Hong Y; Feng Q; Pan X; Song S; Cui J; Lei J; Fang H; Yang J
    Mol Ther Oncolytics; 2018 Dec; 11():90-101. PubMed ID: 30534583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.
    Pan XY; Liu XJ; Li J; Zhen SJ; Liu DX; Feng Q; Zhao WX; Luo Y; Zhang YL; Li HW; Yang JL
    Gene Ther; 2017 Jan; 24(1):40-48. PubMed ID: 27834948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor efficacy of a novel adenovirus-mediated anti-p21Ras single chain fragment variable antibody on human cancers in vitro and in vivo.
    Yang JL; Pan XY; Zhao WX; Hu QC; Ding F; Feng Q; Li GY; Luo Y
    Int J Oncol; 2016 Mar; 48(3):1218-28. PubMed ID: 26780944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor.
    Yu T; Shi Y; Pan X; Feng Q; Wang P; Song S; Yang L; Yang J
    PLoS One; 2022; 17(6):e0269084. PubMed ID: 35648774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues.
    Yang JL; Liu DX; Zhen SJ; Zhou YG; Zhang DJ; Yang LY; Chen HB; Feng Q
    BMC Cancer; 2016 Feb; 16():131. PubMed ID: 26897358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480.
    Huang CC; Liu FR; Feng Q; Pan XY; Song SL; Yang JL
    BMC Cancer; 2021 Mar; 21(1):321. PubMed ID: 33765976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.
    Lin P; Qian J; Huang CC; Xu WM; Wang YY; Gao ZR; Zheng SQ; Wang P; Jia DQ; Feng Q; Yang JL
    BMC Cancer; 2024 Jan; 24(1):71. PubMed ID: 38216883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras.
    Wang P; Pan X; Feng Q; Zou H; Cui J; He Y; Luo Y; Yang J
    Immunotherapy; 2020 Aug; 12(12):879-890. PubMed ID: 32664770
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.
    Du Y; Lin X; Feng Q; Pan X; Song S; Yang J
    Anticancer Drugs; 2022 Jan; 33(1):e562-e572. PubMed ID: 34338241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells.
    Li LX; Zhang YL; Zhou L; Ke ML; Chen JM; Fu X; Ye CL; Wu JX; Liu RY; Huang W
    J Transl Med; 2013 Oct; 11():257. PubMed ID: 24124726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
    Wang XF; Shi ZM; Wang XR; Cao L; Wang YY; Zhang JX; Yin Y; Luo H; Kang CS; Liu N; Jiang T; You YP
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):573-84. PubMed ID: 22207524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains.
    Cochet O; Kenigsberg M; Delumeau I; Duchesne M; Schweighoffer F; Tocqué B; Teillaud JL
    Mol Immunol; 1998 Dec; 35(17):1097-110. PubMed ID: 10395199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
    Yoon SH; Lee JM; Woo SJ; Park MJ; Park JS; Kim HS; Park MY; Sohn HJ; Kim TG
    J Clin Immunol; 2009 Nov; 29(6):806-14. PubMed ID: 19517218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
    Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
    Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.